Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma

These expert recommendations were developed to help clinicians better monitor patients receiving T-cell engaging therapies (e.g., bispecifics such as teclistamab and elranatamab) and help institutions create protocols to facilitate their outpatient delivery.